Secular trends (1990-2013) in serotypes and associated non-susceptibility of S. pneumoniae isolates causing invasive disease in the pre-/post-era of pneumococcal conjugate vaccines in Spanish regions without universal paediatric pneumococcal vaccination

Vaccine

Volumn 33, Issue 42, 2015, Pages 5691-5699

  Fenoll, Asunción ^a   Granizo, Juan José ^b   Giménez, María José ^c   Yuste, José ^a   Aguilar, Lorenzo ^c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL INFANTA CRISTINA   (Spain)

^c PRISM AG   (Spain)

Author keywords

Erythromycin; Levofloxacin; PCV13; Penicillin; Vaccine coverage

Indexed keywords

ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHILD; HUMAN; NONHUMAN; PNEUMOCOCCAL INFECTION; PREVALENCE; PRIORITY JOURNAL; SEROTYPE; SPAIN; STREPTOCOCCUS PNEUMONIAE; VACCINATION; CLASSIFICATION; ISOLATION AND PURIFICATION; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; TRENDS;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROGROUP; SPAIN; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84943425679     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.08.009     Document Type: Article

References (30)

1. Fenoll A., Granizo J.J., Aguilar L., Giménez M.J., Aragoneses-Fenoll L., Hanquet G., et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009, 47:1012-1020.
2. Demczuk W.H., Martin I., Griffith A., Lefebvre B., McGeer A., Lovgren M., et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol 2013, 59:778-788.
3. Ben-Shimol S., Greenberg D., Givon-Lavi N., Schlesinger Y., Somekh E., Aviner S., et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine 2014, 32:3452-3459.
4. Aguiar S.I., Brito M.J., Horacio A.N., Lopes J.P., Ramirez M., Melo-Cristino J., et al. Decreasing incidence and changes in serotype distribution of invasive pneumococcal disease in persons aged under 18 years since introduction of 10-valent and 13-valent conjugate vaccines in Portugal, July 2008 to June 2012. Euro Surveill 2014, 19:20750.
5. Richter S.S., Diekema D.J., Heilmann K.P., Dohrn C.L., Riahi F., Doern G.V. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother 2014, 58:6484-6489.
6. Grupo de Trabajo de la Ponencia de Registro y Programa de Vacunas Enfermedad invasora por Streptococcus pneumoniae. Implicación de la vacunación con la vacuna conjugada heptavalente 2006, Ministerio de Sanidad y Consumo, Madrid, Spain, Available at http://www.murciasalud.es/recursos/ficheros/84893-neumococo_mayo2006.pdf [accessed 10.04.15].
7. Loughlin A.M., Hsu K., Silverio A.L., Marchant C.D., Pelton S.I. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts' children. Pediatr Infect Dis J 2014, 33:504-510.
8. Cobey S., Lipsitch M. Niche and neutral effects of acquired immunity permit coexistence of pneumococcal serotypes. Science 2012, 335:1376-1380.
9. Link-Gelles R., Thomas A., Lynfield R., Petit S., Schaffner W., Harrison L., et al. Geographic and temporal trends in antimicrobial non-susceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States. J Infect Dis 2013, 208:1266-1273.
10. Fenoll A., Asensio G., Jado I., Berrón S., Camacho M.T., Ortega M., et al. Antimicrobial susceptibility and pneumococcal serotypes. J Antimicrob Chemother 2002, 50(Suppl. S2):13-19.
11. García-Rey C., Aguilar L., Baquero F., Casal J., Dal-Ré R. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol 2002, 40:159-164.
12. Farrell D.J., Klugman K.P., Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007, 26:123-128.
13. Fenoll A., Jado I., Vicioso D., Casal J. Dot blot assay for the serotyping of pneumococci. J Clin Microbiol 1997, 35:764-766.
14. Tarragó D., Fenoll A., Sánchez-Tatay D., Arroyo L.A., Muñoz-Almagro C., Esteva C., et al. Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR. Clin Microbiol Infect 2008, 14:828-834.
15. Fenoll A., Martín Bourgon C., Muñóz R., Vicioso D., Casal J. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev Infect Dis 1991, 13:56-60.
16. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacterial that grow aerobically. Approved standard M7-A7 2006, Clinical and Laboratory Standards Institute, Wayne, PA. 7th ed.
17. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; 18th informational supplement. CLSI document M100-S18 2008, Clinical and Laboratory Standards Institute, Wayne, PA.
18. Granizo J.J., Aguilar L., Casal J., García-Rey C., Dal-Ré R., Baquero F. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). J Antimicrob Chemother 2000, 46:767-773.
19. Waight P.A., Andrews N.J., Ladhani S.N., Sheppard C.L., Slack M.P., Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015, 15:535-543.
20. Weil-Olivier C., Gaillat J. Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults?. Vaccine 2014, 32:2022-2026.
21. Harboe Z.B., Dalby T., Weinberger D.M., Benfield T., Mølbak K., Slotved H.C., et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014, 59:1066-1073.
22. Moore M.R., Link-Gelles R., Schaffner W., Lynfield R., Lexau C., Bennett N.M., et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015, 15:301-309.
23. Van Mens S.P., Van Deursen A.M., Meijvis S.C., Vlaminckx B.J., Sanders E.A., De Melker H.E., et al. Increased incidence of serotype-1 invasive pneumococcal disease in young female adults in the Netherlands. Epidemiol Infect 2014, 142:1996-1999.
24. Esteva C., Selva L., de Sevilla M.F., Garcia-Garcia J.J., Pallares R., Muñoz-Almagro C. Streptococcus pneumoniae serotype 1 causing invasive disease among children in Barcelona over a 20-year period (1989-2008). Clin Microbiol Infect 2011, 17:1441-1444.
25. Fletcher M.A., Schmitt H.J., Syrochkina M., Sylvester G. Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology. Eur J Clin Microbiol Infect Dis 2014, 33:879-910.
26. Picazo J., Ruiz-Contreras J., Casado-Flores J., Giangaspro E., Del Castillo F., Hernández-Sampelayo T., et al. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar. Clin Vaccine Immunol 2011, 18:89-94.
27. Picazo J., Ruiz-Contreras J., Casado-Flores J., Negreira S., García-de-Miguel M.J., Hernández-Sampelayo T., et al. Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain. Clin Vaccine Immunol 2013, 20:1524-1530.
28. Picazo J., Ruiz-Contreras J., Casado-Flores J., Giangaspro E., García-de-Miguel M.J., Hernández-Sampelayo T., et al. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011. Pediatr Infect Dis J 2013, 32:656-661.
29. Cohen R., Levy C., Bingen E., Koskas M., Nave I., Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012, 31:297-301.
30. Gervaix A., Ansaldi F., Brito-Avô A., Azzari C., Knuf M., Martinón-Torres F., et al. Pneumococcal vaccination in Europe: schedule adherence. Clin Ther 2014, 36:802-812. e1.